This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos andLiving Beyond Breast Cancer, and is supported by Lilly.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
